The AI engine is offline (last seen Oct 31, 10:31 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
recent 3 years
now +0.27
Recent mood · last 3 years
bearish −1 +1 bullish
-0.75 -0.38 0 +0.38 +0.75 2024 2025 -0.30 2026 +0.51
Full history since 1969-01 ▾
1969-01 → 2026-10 · 694 monthly reads
News · healthcare

The biggest healthcare stories of the last 3 years.

US-China trade truce on critical minerals may expire, risking shortages
The US-China trade truce on critical minerals, agreed on October 30, 2025, in Busan, South Korea, and extended by 60 days to January 10, 2027, faces expiration, risking global supply chain shortages. China suspended export restrictions on at least 22 minerals and materials, including rare earth elements, which if fully enforced, could disrupt up to $6.5 trillion per year of downstream production outside China, per the International Energy Agency. The deal also suspended the BIS Entity List 50% Affiliates Rule. If not extended, industries like medical devices, aerospace, military, automotive, and electronics would face severe shortages, as alternative supplies outside China are inadequate—only 25% of battery demand could be met. Companies would struggle with China's unreliable export license process, risking long delays and overwhelming the system.
z2data.com Sep 24, 2026
Biden Administration Announces First Medicare Drug Prices, Projecting $6B in Savings
The Biden administration revealed negotiated prices for 10 high-cost Medicare drugs, projecting $6 billion in savings for the program and $1.5 billion in out-of-pocket savings for enrollees by 2026. The move, enabled by the Inflation Reduction Act, marks a shift in U.S. drug pricing policy, setting a precedent for future negotiations with major pharmaceutical companies including Merck, Eli Lilly, and Johnson & Johnson. While patient advocates applaud the effort, the industry warns of reduced innovation and ongoing legal challenges.
cnbc.com Aug 15, 2024
Helium supply crisis deepens amid Iran war and Qatar damage
A global helium shortage has worsened seven months after Iranian strikes on Qatar's Ras Laffan facility and the closure of the Strait of Hormuz, which trapped one-third of global supply. Qatar, the second-largest producer after the U.S., may take three years to fully restore operations. Helium is critical for semiconductors, MRI machines, weapons production, and scientific research, with no substitute. Spot prices have tripled since the war began. U.S. exports are up 70%, but cannot offset the shortage indefinitely. Suppliers have imposed rationing, forcing labs and manufacturers to cut usage by 50%. The Pentagon's demand for weapons further strains supply, and the conflict's duration remains uncertain.
cbsnews.com Oct 18, 2026
China proposes new tech export bans on AI, biotech, solar
China proposed new export bans on 14 technologies in AI, biotechnology, and solar power, with additional restrictions on 26 more. The draft, issued Friday by the Ministry of Commerce and Ministry of Science and Technology, targets advanced AI models, agents, computing clusters, certain cell and gene therapy platforms, and solar cell module production tech. Public-domain technologies like open-source systems and published academic work are exempt.
scmp.com Oct 16, 2026
Trump announces 100% tariffs on imported generic drugs starting 2028
President Trump announced via social media a plan to impose 100% tariffs on imported generic drugs starting in August 2028, escalating to 200% after one year, to force manufacturers to move production to the U.S. The proposal targets a nearly $500 billion global industry where generics account for 90% of U.S. prescriptions; India supplies over 50% of these drugs, and China provides most active pharmaceutical ingredients. Industry experts and representatives expressed skepticism, noting generic manufacturers operate on single-digit margins, making the tariffs effectively a "market-exit notice." Building domestic manufacturing takes at least four to five years, according to India's Pharmexcil chairman, suggesting the two-year tariff-free period may be insufficient. The Association for Accessible Medicines called for broader policy changes. Companies with existing U.S. production, like Amphastar and Hikma, are better positioned, while Teva and Viatris face greater exposure. It remains unclear if tariffs apply to finished drugs only or also to those using imported ingredients. New reporting highlights that generic drugmakers, unlike patented pharma giants like Johnson & Johnson and Eli Lilly, operate on thin margins due to price wars—prices can fall 70% in two years after patent expiry—making reshoring less viable. Erez Israeli, CEO of Dr. Reddy's, stated tariffs would force price increases in the U.S., and the Global Trade Research Initiative noted many Indian generics would remain cost-competitive even after 100% tariffs, with costs likely passed to patients, insurers, and providers.
cnbc.com Jul 22, 2026
Market rotates from tech to defensive sectors; oil spikes
Markets are rotating from technology and communications services into defensive sectors like healthcare, utilities and consumer staples, while the S&P 500 remains broadly stable. Global oil prices have spiked back toward 2026 highs. The probability of a Federal Reserve rate hike at its October meeting has dropped from about 70% in September to under 10%, while odds of a Canadian rate hike have risen above 80%. Credit default swap prices on U.S. hyperscaler debt have increased this year, and the share of leveraged ETFs holding a single stock has climbed 12 percentage points since 2024 to 28% in 2026.
edwardjones.ca Oct 23, 2026
China unveils 2030 plan to lead global biomedical innovation
China has unveiled a 2030 plan to become a global leader in biomedical innovation, targeting 25% of the world's first-in-class drugs and 3.5 trillion yuan ($520bn) in annual industry revenue. The initiative, announced via a joint ministerial notice, outlines 25 priority tasks including ramping up R&D, using AI and quantum computing in drug discovery, and building pharma ecosystems. It aims for 50 companies with over $1.5bn in annual revenue and at least five Chinese drugs achieving $1bn in global sales. Emphasis is on next-generation therapies like ADCs, cell and gene therapies, and mRNA vaccines, alongside modernizing traditional Chinese medicine. Citi analysts described the plan as a shift from scale-driven to innovation-driven growth.
finance.yahoo.com Sep 21, 2026
Hot PCE Inflation Spurs Defensive ETF Rotation as Rate Hopes Fade
The July Personal Consumption Expenditures (PCE) price index rose 3.7% year over year, topping economists' 3.6% estimate and remaining well above the Federal Reserve's 2% target, while core PCE held at 3.3% and monthly headline and core PCE both increased 0.2%. This hot inflation reading pushed Treasury yields higher and dampened rate-cut hopes, prompting investors to rotate into defensive ETFs. Funds like the Consumer Staples Select Sector SPDR ETF (XLP), Health Care Select Sector SPDR ETF (XLV), Utilities Select Sector SPDR ETF (XLU), Vanguard Health Care ETF (VHT), and Invesco S&P 500 Low Volatility ETF (SPLV) offer exposure to less cyclical sectors such as staples, healthcare, and utilities, or lower-volatility stocks, providing a steadier path amid persistent inflation and rising rates. XLP's top holdings include Walmart, Costco, and Procter & Gamble, while XLU's capital-intensive nature keeps it sensitive to interest rates, with State Street holding a neutral view on utilities. SPLV selects the 100 least volatile S&P 500 stocks to reduce portfolio volatility.
benzinga.com Aug 26, 2026
58% Chance of Fed Rate Hike in October; 3 Stocks to Buy
The Federal Reserve may raise interest rates in October, with CME Group's FedWatch tool showing a 57.7% probability of a hike at the late-October FOMC meeting, following a 44.1% chance in September. Despite the potential for rising rates to hurt many stocks, three are recommended as buys: UnitedHealth Group, which has seen a 20% year-to-date gain and a 54% earnings jump in Q2 2026; JPMorgan Chase, which benefits from higher net interest income, reporting $25.6 billion in Q2; and Chevron, which gains from elevated fuel prices tied to the Iran war and resurging inflation, with shares up over 20% in 2026.
finance.yahoo.com Aug 09, 2026
Health insurance premiums jump 9%, uninsured rate rises to 11.2%
Health insurance premiums for family plans jumped 9% in 2026, averaging $7,471, according to KFF's survey, driven by rising healthcare costs and pushing small businesses to drop coverage. Concurrently, the uninsured rate among working-age adults rose to 11.2% in 2026, up from 8.9% in 2024, per the Commonwealth Fund, due to expired ACA premium tax credits and rolled-back Medicaid protections. Half of uninsured adults forwent needed care due to cost. Experts warn that further Medicaid cuts and ACA restrictions in 2027 will worsen access.
statnews.com Oct 22, 2026
US Visa Rules Threaten Biotech Talent Pipeline, Warns Expert
Dr. Fanta Aw, executive director of NAFSA, warns that U.S. immigration policy is driving away international life sciences talent, risking the country's leadership in biotech innovation. A proposed four-year cap on student visas, blocked by a federal judge on September 14, would have forced all international PhD students to seek extensions, as no U.S. PhD program is four years. Aw argues the cap is a 'solution in search of a problem,' given the existing SEVIS tracking system. Broader policies—including travel bans, social media screening, and visa revocations for minor infractions—have created a climate of fear. International students comprise nearly 60% of U.S. life sciences postdocs, but page views for U.S. PhD programs have dropped 40% or more, and STEM PhD enrollments fell by 47,000 in 2025-2026. Meanwhile, countries like Germany and South Korea are actively recruiting these scientists. Aw warns that once trust is lost, it will be difficult to rebuild, and the next major biotech breakthrough may occur outside the U.S.
finance.biggo.com Sep 17, 2026
Eli Lilly Grows 55.5% in Q1 2026; Foundayo Oral GLP-1 Cleared
Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.5% year-over-year, beating consensus estimates, and raised full-year guidance by $2 billion. The FDA cleared Foundayo, the first any-time-of-day oral GLP-1 drug, which drove 80% new-to-class prescriptions in early launch data. Mounjaro revenue surged 125% to $8.66 billion, and Zepbound rose 80% to $4.16 billion. The company also completed a $6.3 billion Centessa acquisition and a $6.5 billion manufacturing plant investment. However, realized prices fell 13% amid volume gains, and Novo Nordisk filed a false-advertising lawsuit. 24/7 Wall St. set a $1,365.51 price target with a buy rating, citing Foundayo's potential to expand the oral obesity market globally.
247wallst.com Jul 24, 2026